Full Press Release Details
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024.
ALT
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Key Takeaway: Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
Price reaction · baseline $8.74 (2024-03-19 close) · hit after-hours · clean, no other ALT news in the window
day 0 close · peak
+6.9%
day 1
+4.2%
day 3
-2.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight